ArticleBMC infectious diseases2025
The impact of Omicron infection on antibody response and attenuation: a six-month follow-up study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAntibody patterns to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are the subject of the current study, and the variations in antibodies to Omicron are yet unknown. The study investigated the 6-month longitudinal dynamics and influencing factors of antibodies, including immunoglobulin (Ig) G, IgM, and neutralizing antibodies (NAbs), in healthcare workers (HCWs) following Omicron infection.
methodsThe prospective cross-sectional study in Shanghai recruited HCWs testing positive for Omicron through multistage sampling, and were followed up six times with blood sampling and questionnaires. The titers of the specific NAb against Omicron and the cut-off index (COI) of IgG/IgM against Omicron were tested by chemiluminescent immunoassay. Antibody decay models were developed based on individual data from participants with the single Omicron infection, and statistical analyses were conducted using Mann-Whitney U and Kruskal-Wallis tests.
resultsA total of 710 HCWs were enrolled. After the single infection, IgG exhibited a mean short-term increase of 70.07 COI and a long-term elevation of 33.63 COI, with a gradual decline at a rate of - 0.0024 COI per day. IgM demonstrated a transient elevation, with a short-term boost of 23.66 COI and a modest long-term increase of 0.63, followed by a more rapid decay at - 0.0664 COI per day. NAb similarly rose significantly post-infection, with a short-term increase of 295.28 antibody units (AU)/ml and a sustained long-term elevation of 292.07 AU/ml, declining at a rate of - 0.0021 AU/ml per day. IgG and NAb remained high for 5 months but declined significantly in the sixth, while IgM declined rapidly throughout. Reinfection occurred in 36.76% of HCWs, boosting antibody levels. Timing between infection and vaccination significantly influenced the waning of IgG/IgM but not NAbs. No associations were found between antibody decay and demographic or clinical factors.
conclusionWhile Omicron infection induces robust short-term antibody responses, immunity wanes significantly within 6 months, and reinfection temporarily boosts antibody levels. The findings highlight the limited durability of natural and hybrid immunity and underscore the need for timely booster vaccinations to sustain protection, particularly in high-risk groups like HCWs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.